This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Zerit

Bristol-Myers Squibb Company

Drug Names(s): Stavudine, d4T

Description: Zerit (Stavudine, d4T) is a synthetic thymidine nucleoside analogue with activity against the human immunodeficiency virus (HIV). Stavudine inhibits the activity of HIV-1 reverse transcriptase (RT) by competing with the natural substrate thymidine triphosphate and by causing DNA chain termination following its incorporation into viral DNA.

Deal Structure: DRI Capital
On an undisclosed date, DRI Capital purchased royalties relating to the sales of Zerit for HIV. As a result of this transaction, DRI Capital, through its managed private equity funds, owns royalty entitlements for this drug for an undisclosed rate.

Partners: DRI Capital Inc.


Zerit News

Pink Sheet Bristol Zerit XR

Pink Sheet Zerit


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug